Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32308
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRyan, Marissa-
dc.contributor.authorLam, Neil-
dc.contributor.authorWright, Kate-
dc.contributor.authorSiderov, Jim-
dc.date2023-
dc.date.accessioned2023-03-22T01:49:19Z-
dc.date.available2023-03-22T01:49:19Z-
dc.date.issued2023-12-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology 2023-12; 19(6)en_US
dc.identifier.issn1743-7563-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32308-
dc.description.abstractThe aims were to (a) review the scientific literature on occupational risk, including exposure mechanisms and risk assessment, with regards to handling monoclonal antibodies (mABs) in healthcare settings; and (b) update the recommendations in the Clinical Oncology Society of Australia (COSA) safe handling of monoclonal antibodies in healthcare settings position statement, published in 2013. A literature search was conducted between April 24, 2022, and July 3, 2022, to identify evidence relating to occupational exposure and handling of mABs in healthcare settings. Evidence in the literature was compared to the Position Statement published in 2013, and any potential additions, deletions, or revisions were discussed by the authors, and then agreed changes were made. Thirty-nine references were included in this update, comprising of the 2013 Position Statement itself and 10 of its references, as well as 28 new references. The risks to healthcare workers in the preparation and administration of mABs arise from four distinct exposure mechanisms: dermal, mucosal, inhalation, and oral. Updates included recommendations on using protective eyewear during the preparation and administration of mABs, developing a local institutional risk assessment tool and handling recommendations, considerations for using closed system transfer devices, and to have awareness of the nomenclature change from 2021 for new mABs. Practitioners should follow the 14 recommendations to lower occupational risk when handling mABs. Another Position Statement update should occur in 5-10 years to ensure the currency of recommendations.en_US
dc.language.isoeng-
dc.subjectcancer servicesen_US
dc.subjectmonoclonal antibodiesen_US
dc.subjectoncologyen_US
dc.subjectpharmacyen_US
dc.subjectsafe handlingen_US
dc.titleClinical Oncology Society of Australia Position Statement: 2022 update to the safe handling of monoclonal antibodies in healthcare settings.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAsia-Pacific Journal of Clinical Oncologyen_US
dc.identifier.affiliationDepartment of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia.en_US
dc.identifier.affiliationIcon Cancer Centre River City Pharmacy, Brisbane, Australia.en_US
dc.identifier.affiliationCentral West Cancer Care Centre, Orange, Australia.en_US
dc.identifier.affiliationPharmacyen_US
dc.identifier.doi10.1111/ajco.13943en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-9223-0740en_US
dc.identifier.orcid0000-0003-3949-1671en_US
dc.identifier.orcid0000-0003-1379-5095en_US
dc.identifier.orcid0000-0002-9562-083Xen_US
dc.identifier.pubmedid36899469-
local.name.researcherSiderov, Jim-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.